171 related articles for article (PubMed ID: 34265474)
1. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply.
Du K; Li S; Li C; Li P; Miao C; Luo T; Qiu B; Ding W
Acta Biomater; 2021 Oct; 134():228-239. PubMed ID: 34265474
[TBL] [Abstract][Full Text] [Related]
2. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System.
Wang Y; Wang H; Deng P; Tao T; Liu H; Wu S; Chen W; Qin J
ACS Biomater Sci Eng; 2020 Oct; 6(10):5734-5743. PubMed ID: 33320545
[TBL] [Abstract][Full Text] [Related]
3. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study.
Gori M; Giannitelli SM; Zancla A; Mozetic P; Trombetta M; Merendino N; Rainer A
Biotechnol Bioeng; 2021 Jan; 118(1):142-152. PubMed ID: 32889748
[TBL] [Abstract][Full Text] [Related]
4. A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease.
Lasli S; Kim HJ; Lee K; Suurmond CE; Goudie M; Bandaru P; Sun W; Zhang S; Zhang N; Ahadian S; Dokmeci MR; Lee J; Khademhosseini A
Adv Biosyst; 2019 Aug; 3(8):e1900104. PubMed ID: 32648699
[TBL] [Abstract][Full Text] [Related]
5. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device.
Gori M; Simonelli MC; Giannitelli SM; Businaro L; Trombetta M; Rainer A
PLoS One; 2016; 11(7):e0159729. PubMed ID: 27438262
[TBL] [Abstract][Full Text] [Related]
6. A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation.
Bulutoglu B; Rey-Bedón C; Kang YBA; Mert S; Yarmush ML; Usta OB
Lab Chip; 2019 Sep; 19(18):3022-3031. PubMed ID: 31465069
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems.
Soto-Gutierrez A; Gough A; Vernetti LA; Taylor DL; Monga SP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1605-1616. PubMed ID: 28467181
[TBL] [Abstract][Full Text] [Related]
9. Modeling Colorectal Cancer-Induced Liver Portal Vein Microthrombus on a Hepatic Lobule Chip.
Du X; Zou R; Du K; Huang D; Miao C; Qiu B; Ding W; Li C
ACS Appl Mater Interfaces; 2023 Nov; ():. PubMed ID: 38033197
[TBL] [Abstract][Full Text] [Related]
10.
Shi Y; Pizzini J; Wang H; Das F; Abdul Azees PA; Ghosh Choudhury G; Barnes JL; Zang M; Weintraub ST; Yeh CK; Katz MS; Kamat A
Am J Physiol Endocrinol Metab; 2021 Jul; 321(1):E90-E104. PubMed ID: 34029162
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
12. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
13. Modeling Nonalcoholic Fatty Liver Disease in the Dish Using Human-Specific Platforms: Strategies and Limitations.
Rezvani M; Vallier L; Guillot A
Cell Mol Gastroenterol Hepatol; 2023; 15(5):1135-1145. PubMed ID: 36740045
[TBL] [Abstract][Full Text] [Related]
14. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
15. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
17. Genetically modified mouse models for the study of nonalcoholic fatty liver disease.
Nagarajan P; Mahesh Kumar MJ; Venkatesan R; Majundar SS; Juyal RC
World J Gastroenterol; 2012 Mar; 18(11):1141-53. PubMed ID: 22468076
[TBL] [Abstract][Full Text] [Related]
18. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
